Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06539221

Sphingolipids in Asthma Pathogenesis

The study aims to investigate the relationship between the small molecule metabolite sphingolipids and asthma clinical features and explore its involvement in asthma pathogenesis.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking university third hospital

Beijing, Beijing Municipality, 100191, China

Location contact

Chun Chang

CONTACT

[email protected]

15810075362

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. clinical diagnosis of asthma

Exclusion criteria

  • 1. Combined with chronic obstructive pulmonary disease, bronchiectasis, pneumonia, obstructive sleep apnea hypopnea syndrome, malignant tumor 2. Combined with acute and chronic respiratory failure 3. Combined with severe cardiovascular disease 4. Pregnant woman.

Treatment and study plan

Primary outcomes

  1. lipidomics

    Time frame: Day 1

    collect blood for lipidomic analysis and in vitro assays

Study contacts

Contact information is provided by the study sponsor or research team.

Chun Chang

CONTACT

[email protected]

15810075362

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Official study title

Sphingomyelin in Asthma Pathogenesis

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Aug 6, 2024
Registry last updated
Aug 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.